ZNF827 and cancer: Depletion of ZNF827 was shown to impair homologous recombination mediated repair and sensitized cancer cells to treatment with the topoisomerase I inhibitor topotecan, thereby identifying ZNF827 as a potential new therapeutic target (Yang et al., 2024).